Tabuk Pharmaceutical Manufacturing Company, one of the leading pharmaceutical companies in the Middle East and North Africa (Mena) region, has entered into a license and supply agreement with Swiss-based Selectchemie.

Under the agreement, Selectchemie has granted Tabuk a license to register, market and sell Caspofungin Injection (systemic antifungal agent) in Gulf countries, North Africa, and the rest of Middle East.

Selectchemie is one of the leading European companies, headquartered in Zurich serving the pharmaceutical and human nutrition industries since 1969 as a premier supplier of high quality ingredients.

Dr Rana Azzam, senior VP of business development, said: "We are excited about this major partnership collaboration with Selectchemie. Caspofungin Injection is a hard to develop and lifesaving product. This partnership will provide an opportunity for both companies to leverage their combined strength."  -TradeArabia News Service